In vitro efficacy of polysaccharide-based nanoparticles containing disease-modifying antirheumatic drugs

Pharmaceutical Research

Volumn 31, Issue 9, 2014, Pages 2326-2334

  Zhang, Nan ^a   Wardwell, Patricia R ^a   Bader, Rebecca A ^a  

^a Syracuse University   (United States)

Author keywords

chitosan; drug delivery; nanoparticles; polysialic acid; rheumatoid arthritis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CHITOSAN; DEXAMETHASONE; DRUG CARRIER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; NANOPARTICLE; POLYSIALIC ACID; SIALIC ACID DERIVATIVE;

ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; CELL LINE; CHEMISTRY; CYTOLOGY; HUMAN; IMMUNOLOGY; SYNOVIUM;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL LINE; CHITOSAN; DEXAMETHASONE; DRUG CARRIERS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; METHOTREXATE; NANOPARTICLES; SIALIC ACIDS; SYNOVIAL MEMBRANE;

EID: 84894628160     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1329-z     Document Type: Article

References (57)

1. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54(2):205-18.
2. Weinblatt ME, Kremer JM. Methotrexate in rheumatoid arthritis. J Am Acad Dermatol. 1988;19(1 Pt 1):126-8.
3. Mottram PL. Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol. 2003;81(5):350-3.
4. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin N Am. 1994;20(2):513-28.
5. Wolverton SE, Remlinger K. Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs. Dermatol Clin. 2007;25(2):195-205. vi-ii.
6. Baschant U, Lane NE, Tuckermann J. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol. 2012;8(11):645-55.
7. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60(15):1650-62.
8. Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv. 2005;12(1):41-57.
9. Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm. 2002;249(1-2):165-74.
10. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73(2-3):255-67.
11. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16(10):1576-81.
12. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115(2):216-25.
13. Zhang N, Bader RA. Synthesis and characterization of polysialic acid-N-Trimethyl chitosan nanoparticles for drug delivery. NanoLIFE. 2012;2(3):1241003.
14. Jain S, Hreczuk-Hirst DH, McCormack B, Mital M, Epenetos A, Laing P, et al. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta. 2003;1622(1):42-9.
15. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm. 2001;217(1-2):215-24.
16. Fernandes AI, Gregoriadis G. Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochim Biophys Acta. 1997;1341(1):26-34.
17. Fernandes AGG. FC41 catalase-polysialic acid conjugates. Eur J Pharm Sci. 1994;2(1-2):111.
18. Fernandes AI, Gregoriadis G. Synthesis, characterization and properties of sialylated catalase. Biochim Biophys Acta. 1996;1293(1):90-6.
19. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm [Article]. 2005;300(1-2):125-30.
20. Gregoriadis G, Fernandes A, Mital M, McCormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci. 2000;57(13-14):1964-9.
21. Gregoriadis G, Fernandes A, McCormack B, Mital M, Zhang X. Polysialic acids: potential role in therapeutic constructs. Biotechnol Genet Eng Rev. 1999;16:203-15.
22. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2000;2(5):356-60.
23. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42.
24. Yamazaki T, Yokoyama T, Akatsu H, Tukiyama T, Tokiwa T. Phenotypic characterization of a human synovial sarcoma cell line, SW982, and its response to dexamethasone. In Vitro Cell Dev Biol-Anim. 2003;39(8-9):337-9.
25. Choi EM, Lee YS. Luteolin suppresses IL-1 beta-induced cytokines and MMPs production via p38 MAPK, JNK, NF-kappaB and AP-1 activation in human synovial sarcoma cell line, SW982. Food Chem Toxicol. 2010;48(10):2607-11.
26. Wada Y, Shimada K, Kimura T, Ushiyama S. Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982. Immunol Lett. 2005;101(1):50-9.
27. Wagoner KL, Bader RA. Evaluation of SV40-transformed synovial fibroblasts in the study of rheumatoid arthritis pathogenesis. Rheumatol Int. 2012;32(7):1885-91.
28. Polakovic M, Gorner T, Gref R, Dellacherie E. Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. J Control Release. 1999;60(2-3):169-77.
29. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45(6):669-75.
30. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2(5):361-7.
31. Boddohi S, Moore N, Johnson PA, Kipper MJ. Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan. Biomacromolecules. 2009;10(6):1402-9.
32. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev. 2001;47(1):83-97.
33. Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo). 2010;58(11):1423-30.
34. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48(6):1521-9.
35. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001;167(9):5381-5.
36. Koch AE. Chemokines and their receptors in rheumatoid arthritis future targets? Arthritis Rheum. 2005;52(3):710-21.
37. Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol. 1995;34(7):602-9.
38. Maillefert JF, Puechal X, Falgarone G, Lizard G, Ornetti P, Solau E, et al. Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Joint Bone Spine. 2010;77(6):558-63.
39. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60(8):729-35.
40. Chan ESL, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol. 2010;6(3):175-8.
41. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4(4):266-73.
42. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163-72.
43. Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, et al. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology. 2000;47(1):35-44.
44. Seitz M, Loetscher P, Dewald B, Towbin H, Baggiolini M. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. J Rheumatol. 1997;24(8):1471-6.
45. Inoue H, Takamori M, Nagata N, Nishikawa T, Oda H, Yamamoto S, et al. An investigation of cell proliferation and soluble mediators induced by interleukin 1beta in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. Inflamm Res. 2001;50(2):65-72.
46. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006;58(4):473-92.
47. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-Kappa-B by activated glucocorticoid receptors. Mol Cell Biol. 1995;15(2):943-53.
48. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139(5):359-70.
49. Leung DYM, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111(1):3-23.
50. Muller-Ladner U, Nishioka K. p53 in rheumatoid arthritis: friend or foe? Arthritis Res. 2000;2(3):175-8.
51. Tan PL, Farmiloe S, Yeoman S, Watson JD. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol. 1990;17(12):1608-12.
52. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis. 1993;99(2):241-52.
53. Hamilton JA, Piccoli DS, Cebon J, Layton JE, Rathanaswani P, McColl SR, et al. Cytokine regulation of colony-stimulating factor (CSF) production in cultured human synovial fibroblasts. II. Similarities and differences in the control of interleukin-1 induction of granulocyte-macrophage CSF and granulocyte-CSF production. Blood. 1992;79(6):1413-9.
54. Rodrigues S, Dionisio M, Lopez CR, Grenha A. Biocompatibility of chitosan carriers with application in drug delivery. Funct Biomater. 2012;3:615-41.
55. Guzman-Morales J, Ariganello MB, Hammami I, Thibault M, Jolicoeur M, Hoemann CD. Biodegradable chitosan particles induce chemokine release and negligible arginase-1 activity compared to IL-4 in murine bone marrow-derived macrophages. Biochem Biophys Res Commun. 2011;405(4):538-44.
56. Witschi C, Mrsny RJ. In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery. Pharm Res. 1999;16(3):382-90.
57. Li X, Min M, Du N, Gu Y, Hode T, Naylor M, et al. Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol. 2013;2013:387023.